Clinical and basic research of therapy with sinomenine for pimary membranous nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047996

Enrollment

Unknown

Registered

2021-06-28

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PRIMARY MEMBRANOUS NEPHROPATHY

Interventions

experimental group:Sinomenine 120mg orally intake twice a day

control group:Placebo 120mg orally intake twice a day

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. PMN adults diagnosed by renal biopsy regardless of gender and nation; 2. PMN patients among low risk group and middle risk group without risk factors; 3. Signed Informed Consent; 4. No usage of glucocorticoid or immunosuppressives within 3 months.

Exclusion criteria

Exclusion criteria: 1. PMN patients among high risk and very high risk group,or middle risk group with risk factors. 2. Infection,pregnant,trauma; 3. Serious systemic diseases; 4. Hematological sysyten diseases; 5. Allergic to Sinomenine; 6. Younger than 18 years old; 7. Attending other clinical trial.

Design outcomes

Primary

Measure	Time frame
24h urine protein quantitation;Serum albumin;Glomerular filtration rate;Immune cells;	—

Countries

China

Contacts

Public ContactLiu Liang

Macau University of Science and Technology

lliu@must.edu.mo+86 15920798553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026